Martine A Rothblatt

UTHR CEO Rothblatt sells 9,500 shares for $5.2M via scheduled 10b5-1 plan (June 24)

Martine A Rothblatt, Chairperson & CEO of United Therapeutics, executed 8 separate sales on 2026-06-24 totaling 9,500 shares for $5,212,519.74 at a blended average price of $548.69. This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2025-11-07 and therefore is scheduled, not discretionary. The sale represents a reduction of -19.0% vs pre-transaction holdings, bringing her non-derivative stake from 50,013 shares to 40,513 shares, though she retains 125,218 shares in stock option holdings. The current stock price of $543.39 is -10.8% from the 52-week high of $609.35, and the sale prices of $545.93 to $553.24 were executed near recent lows, though the 90-day price trend shows +3.9% appreciation. Because this is a scheduled 10b5-1 execution, investors should treat this as programmatic capital diversification rather than a discretionary signal about the company's prospects.

CEO Martine A Rothblatt sold 9,500 shares of UTHR for $5,167,570.77 on 2026-06-23 under 10b5-1 plan; retains 40,513 non-derivative shares plus 134,718 options.

Martine A Rothblatt, Chairperson & CEO of United Therapeutics, executed 7 separate sales totaling 9,500 shares for $5,167,570.77 across a narrow price band ($540.24–$546.00) on 2026-06-23. These sales reduced her non-derivative holdings by 19.0% to 40,513 shares, though she retains 134,718 stock options. The transaction is part of a pre-arranged 10b5-1 trading plan adopted 2025-11-07, meaning it was scheduled rather than discretionary. At the current price of $544.33, the stock is -10.7% from its 52-week high and down 4.2% over 30 days, though the company's fundamentals remain solid with $781.5M in latest quarterly revenue, $274.9M net income, and a P/E of 17.95. The scheduled nature of this sale precludes any inference about insider timing or conviction, but the volume and precision of execution across seven tranches indicates orderly plan management.

Rothblatt (CEO) sells 9,500 shares for $5.1M on 2026-06-22 under 10b5-1 plan; retains 40.5K shares plus options

Martine A Rothblatt, Chairperson & CEO of United Therapeutics, executed 7 separate sales totaling 9,500 shares for $5,108,527.05 on 2026-06-22 at prices ranging from $534.09 to $539.90. This sale represents a 19.0% reduction of her non-derivative holdings (from 50,013 to 40,513 shares), but is part of a pre-arranged 10b5-1 trading plan adopted on 2025-11-07, meaning the transaction was scheduled rather than discretionary. Her derivative holdings (144,218 stock option shares) remain intact post-transaction. At the current price of $544.33, the stock is trading 10.7% below its 52-week high of $609.35 and has declined 4.2% over the past 30 days. The company shows solid fundamentals with quarterly revenue of $781.5M, net income of $274.9M, and annual revenue growth of 10.6%, with a P/E of 17.95. This appears to be part of ongoing portfolio management execution rather than a discretionary confidence signal, given the scheduled nature of the plan.

CEO Martine Rothblatt sold 9,500 shares at $540.18 avg for $5.1M on 2026-06-18 via 10b5-1 plan

Martine A Rothblatt, Chairperson & CEO of United Therapeutics, executed 13 separate sales totaling 9,500 shares for $5,131,710.85 on 2026-06-18 under a pre-arranged 10b5-1 trading plan adopted on 2025-11-07. The sales reduced her non-derivative holdings from 50,013 to 40,513 shares, representing a 19.0% reduction in that tranche, though she retains 2,910 derivative shares (stock options). The blended transaction price of $540.18 sits near the current price of $538.30 and within the 52-week range of $272.12–$609.35. Because this disposition is scheduled under a 10b5-1 plan rather than discretionary, it does not reflect real-time confidence signals; the plan was established months prior and executes mechanically. The stock has declined 5.3% over the past 30 days and 11.7% from its 52-week high, although it remains up 1.2% over 90 days. This transaction's significance is moderated by its formulaic nature and by the presence of residual option holdings in the executive's name.

CEO Rothblatt executes 8 separate sales totaling 9,500 shares for $5.2M under 10b5-1 plan; retains 40,513 shares plus 12,410 stock options.

Martine A Rothblatt, Chairperson & CEO of United Therapeutics, executed 8 separate sales totaling 9,500 shares for $5,247,801.53 on 2026-06-17, at prices ranging from $548.57 to $554.77 with a blended average of $552.40. This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2025-11-07, making it scheduled and non-discretionary. Post-transaction, Rothblatt retains 40,513 non-derivative shares (a -19.0% reduction from pre-transaction holdings of 50,013) plus 12,410 shares in stock option holdings, maintaining meaningful exposure to the company. The current stock price of $536.59 is -11.9% from the 52-week high of $609.35 and down 5.3% over 30 days, though the company shows solid fundamentals with P/E of 17.69, annual revenue growth of +10.6%, and net income of $274,900,000. As a scheduled 10b5-1 transaction, this sale reflects predetermined trading mechanics rather than a discretionary timing decision by the CEO.

CEO Martine Rothblatt sells 9,500 shares for $5.2M via 10-tranche scheduled plan; retains 40,513 shares plus 21,910 options.

Martine A Rothblatt, Chairperson & CEO of United Therapeutics, executed 10 separate sales on 2026-06-16 totaling 9,500 shares for $5,223,068.48 at an average price of $549.80, reducing her non-derivative holdings from 50,013 shares to 40,513 shares. This represents a -19.0% reduction in her common stock position, executed via a pre-arranged 10b5-1 trading plan adopted on 2025-11-07, meaning the sales were scheduled and automatic rather than discretionary. Rothblatt's derivative holdings of 21,910 stock options remain intact post-transaction, preserving her material economic exposure to the company. The current stock price of $548.27 is -10.0% from the 52-week high of $609.35, and her sales occurred within a narrow price band ($545.18–$554.63), consistent with systematic execution of a pre-planned schedule rather than a response to current market conditions.

UTHR CEO Rothblatt sells 9,500 shares for $5,216,917.70 via scheduled 10b5-1 plan

Martine A Rothblatt, Chairperson & CEO of United Therapeutics, executed 13 separate sales totaling 9,500 shares for $5,216,917.70 on 2026-06-15, reducing non-derivative holdings from 50,013 shares to 40,513 shares. This transaction was conducted under a pre-arranged 10b5-1 trading plan adopted on 2025-11-07, meaning it follows a scheduled program rather than a discretionary decision. The sale represents a -19.0% reduction in Rothblatt's non-derivative holdings; however, she retains 31,410 shares in derivative securities (stock options), preserving substantial equity exposure. The blended average price of $549.15 occurs near the current market price of $548.27, and the transaction follows five prior UTHR sales completed on 2026-06-12, suggesting an ongoing systematic liquidation schedule across consecutive trading days.

Rothblatt sells 9,500 shares for $5.1M under scheduled 10b5-1 plan; retains 40.5K shares plus 40,910 stock options.

Martine A Rothblatt, Chairperson & CEO of United Therapeutics, executed 9 separate sales on 2026-06-12 totaling 9,500 shares for $5,143,214.25 at prices ranging from $537.40 to $544.45, reducing non-derivative holdings from 50,013 to 40,513 shares. This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2025-11-07, meaning it is scheduled rather than discretionary. After the sale, Rothblatt retains 40,513 shares of common stock plus 40,910 shares via outstanding stock options, indicating meaningful ongoing equity exposure to the company. The current stock price of $549.57 sits 9.8% below the 52-week high of $609.35, and the company shows solid fundamentals with net income of $274,900,000.00 on revenue of $781,500,000.00 and annual revenue growth of 10.6%.

Martine Rothblatt sells 9,500 shares at $5,217,684.49 under 10b5-1 plan; retains 40,513 shares plus derivative holdings

CEO Martine Rothblatt executed 10 separate sales totaling 9,500 shares for $5,217,684.49 on 2026-06-11 under a pre-arranged 10b5-1 trading plan adopted on 2025-11-07, reducing her non-derivative holdings from 50,013 shares to 40,513 shares. This scheduled sale occurs while the stock trades near its 52-week high (current $545.40 is -10.5% from the $609.35 peak) and represents -19.0% of her pre-transaction non-derivative position; she retains 50,410 shares in derivative form. Her prior sales at UTHR showed positive 30-day and 90-day returns (ranging +0.9% to +1.9%), though as a 10b5-1 transaction, this sale is deterministic rather than discretionary. The company reports strong fundamentals with $781,500,000.00 in latest quarterly revenue, $274,900,000.00 net income, and +10.6% annual revenue growth.

UTHR CEO Rothblatt sold 9,500 shares for $5.2M via scheduled 10b5-1 plan on 2026-06-10

Martine A Rothblatt executed 17 separate sales totaling 9,500 shares for $5,185,365.12 on 2026-06-10 under a pre-arranged 10b5-1 trading plan adopted on 2025-11-07, reducing her non-derivative holdings from 50,013 to 40,513 shares. The blended average transaction price of $545.83 is slightly above the current price of $545.40, with the stock down 10.5% from its 52-week high of $609.35 and down 6.2% over the past 30 days. Rothblatt retains 59,910 shares in derivative form (stock options), indicating this represents a partial reduction of non-derivative holdings rather than a complete position exit. The scheduled nature of the 10b5-1 plan removes discretionary timing as a signal; this sale follows a pattern of five prior same-ticker sales on 2026-06-04, all of which showed modest positive returns in the 30 and 90-day windows post-transaction (ranging from +0.9% to +1.9%).